Lifeloc Reports Third Quarter 2026 Results
Lifeloc Technologies, Inc (LCTC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Lifeloc Reports Third Quarter 2026 Results WHEAT RIDGE, Colo., November 16, 2026 -- Lifeloc Technologies, Inc. (OTCID: LCTC), a global leader in the development and manufacturing of breath alcohol and drug testing devices, has announced financial results for the quar
How this was made
The 30-second read
Why it matters
The 8-K furnishes Q3 2026 financial results and a revised commercialization timeline for SpinDetect, shifting the expected path to future revenue and cash-flow funding needs.
Market read
Traders can update expectations for near-term profitability (gross margin and revenue growth) and reprice longer-dated growth optionality due to the SpinDetect launch delay.
What to watch
The company states it will defer core breath-alcohol upgrades and rely on current staff for beta testing, which could affect execution quality and the pace of subsequent multi-drug panel expansion.
Background
Lifeloc Technologies is an OTC-listed manufacturer of evidential breath alcohol testers and is developing the SpinDetect centrifugal drug analyzer platform for rapid on-site quantitative drug detection.
Ticker impact
Lifeloc reports Q3 2026 revenue of $2.522M and updates SpinDetect commercialization timing to a limited launch in Q4 2027.
Shares may see modest support from revenue growth and margin improvement, but upside could be capped by the Q1 2027 to Q4 2027 delay for SpinDetect.
The filing provides fresh quarterly financial datapoints and a specific change to the SpinDetect launch schedule, both directly affecting near-term expectations and longer-dated growth optionality.
Market effects
Highlights ongoing R&D intensity in breath alcohol and drug testing instrumentation, with commercialization risk tied to regulatory and validation timelines.
No clear regional spillover beyond a small OTC issuer’s reporting.
Limited global read-through; the drug analyzer platform is positioned for multiple use cases but remains pre-commercial.
Counterpoint
The improved gross margin may be driven by mix and price increases, while the core growth engine (SpinDetect) is pushed further out, increasing dilution or capital-access risk.
Key entities
- companyLifeloc Technologies, Inc.
OTC-listed developer and manufacturer of breath alcohol and drug testing devices, reporting Q3 2026 results and SpinDetect timeline changes.
- product_platformSpinDetect Centrifugal Drug Analyzer
Oral-fluid centrifugal drug analyzer platform with beta testing planned for delta-9-THC and a revised limited commercial launch expected in Q4 2027.
- product_lineL-series breath alcohol devices
Newer breath alcohol lineup with smartphone pairing and temperature range features, positioned as incremental to FC-series devices.


